Drug intelligence / Profile preview

Jiangniaosuan formula

Development stage: Unknown
Lead developer: Shanghai Pudong Hospital
Administration: Oral

Overview

Jiangniaosuan formula is a traditional Chinese herbal medicine developed by Shanghai Pudong Hospital for the treatment of hyperuricemia and gout. It is typically used as an adjunctive therapy alongside standard xanthine oxidase inhibitors like febuxostat. The formula is designed to reduce and stabilize serum uric acid levels while potentially addressing comorbid conditions such as dyslipidemia and insulin resistance. In clinical studies, it has been evaluated for its ability to improve traditional Chinese medicine (TCM) syndrome scores and maintain therapeutic effects after the cessation of treatment.

Other names: JiangniaosuanJiangniaosuan decoction

Targets

BCL-2 (BCL-2 family)HIF1A (Hypoxia-inducible factor 1-alpha)CASP3 (Caspase-3)EZH2 (Histone-lysine N-methyltransferase EZH2)

Beyond the preview

Go deeper on Jiangniaosuan formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangniaosuan formula.

Explore the full profile